Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
UNICHEM LAB TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
UNICHEM LAB Mar-23 |
TEVA PHARMA Dec-13 |
UNICHEM LAB/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 467 | 3,486 | - | |
Low | Rs | 226 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 190.7 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | -28.7 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | -12.6 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.40 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 344.2 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 70.41 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.8 | 1.6 | 111.6% | |
Avg P/E ratio | x | -12.1 | 26.1 | -46.3% | |
P/CF ratio (eoy) | x | -27.5 | 11.4 | -241.9% | |
Price / Book Value ratio | x | 1.0 | 1.5 | 68.7% | |
Dividend payout | % | 0 | 87.5 | -0.0% | |
Avg Mkt Cap | Rs m | 24,396 | 2,761,843 | 0.9% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 3,564 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 13,430 | 1,696,422 | 0.8% | |
Other income | Rs m | 385 | 0 | - | |
Total revenues | Rs m | 13,815 | 1,696,422 | 0.8% | |
Gross profit | Rs m | -841 | 464,566 | -0.2% | |
Depreciation | Rs m | 1,134 | 137,123 | 0.8% | |
Interest | Rs m | 173 | 33,320 | 0.5% | |
Profit before tax | Rs m | -1,764 | 294,122 | -0.6% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 259 | -3,591 | -7.2% | |
Profit after tax | Rs m | -2,022 | 105,974 | -1.9% | |
Gross profit margin | % | -6.3 | 27.4 | -22.9% | |
Effective tax rate | % | -14.7 | -1.2 | 1,201.2% | |
Net profit margin | % | -15.1 | 6.2 | -241.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,885 | 1,145,757 | 1.4% | |
Current liabilities | Rs m | 6,396 | 999,197 | 0.6% | |
Net working cap to sales | % | 70.7 | 8.6 | 817.8% | |
Current ratio | x | 2.5 | 1.1 | 216.6% | |
Inventory Days | Days | 51 | 91 | 56.4% | |
Debtors Days | Days | 1,600 | 96 | 1,667.9% | |
Net fixed assets | Rs m | 15,911 | 554,089 | 2.9% | |
Share capital | Rs m | 141 | 4,176 | 3.4% | |
Net worth | Rs m | 24,233 | 1,884,403 | 1.3% | |
Long term debt | Rs m | 636 | 867,418 | 0.1% | |
Total assets | Rs m | 31,829 | 3,876,868 | 0.8% | |
Interest coverage | x | -9.2 | 9.8 | -93.5% | |
Debt to equity ratio | x | 0 | 0.5 | 5.7% | |
Sales to assets ratio | x | 0.4 | 0.4 | 96.4% | |
Return on assets | % | -5.8 | 3.6 | -161.7% | |
Return on equity | % | -8.3 | 5.6 | -148.4% | |
Return on capital | % | -6.4 | 4.9 | -129.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -851 | 270,322 | -0.3% | |
From Investments | Rs m | 2,028 | -95,786 | -2.1% | |
From Financial Activity | Rs m | -813 | -324,269 | 0.3% | |
Net Cashflow | Rs m | 746 | -149,733 | -0.5% |
Compare UNICHEM LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare UNICHEM LAB With: VALIANT LABORATORIES LTD. SAKAR HEALTHCARE MEDICO REMEDIES VIVO BIO TECH ASTRAZENECA PHARMA
Indian share markets Slipped further as the session progressed and ended the day weak.